What is Eton Pharmaceuticals Inc (ETON) stock price today?

Eton Pharmaceuticals Inc (ETON) currently trades at $24.12 per share. The stock has a market capitalization of $628.09M and a P/E ratio of —x.

Is ETON stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Eton Pharmaceuticals Inc has a Smart Value Score of 35/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Eton Pharmaceuticals Inc's revenue and earnings?

Eton Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $79.95M with profit margins of -5.76%. Earnings per share (EPS) is $-0.17.

ETON

Eton Pharmaceuticals Inc

NASDAQ: ETON · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$24.12

+2.29% today

Updated 2026-04-30

Market cap

$628.09M

P/E ratio

—

P/S ratio

7.86x

EPS (TTM)

$-0.17

Dividend yield

—

52W range

$13 – $27

Volume

0.4M

Market cap

$628.09M

P/E ratio

—

P/S ratio

7.86x

EPS (TTM)

$-0.17

Dividend yield

—

52W range

$13 – $27

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

7.3

Growth

B+

5.0

Quality

C+

4.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$39.33

+63.06%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 82.70% QoQ

Risks

- Thin margins at -5.76%

- Negative free cash flow $-11.60M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$21.25M	$31.64M	$39.01M	$79.95M	$79.95M
Net income	$-9.02M	$-936000.00	$-3.82M	$-4.60M	$1.48M
EPS	—	—	—	—	$-0.17
Free cash flow	$2.03M	$6.04M	$943000.00	$10.19M	$-11.60M
Profit margin	-42.45%	-2.96%	-9.80%	-5.75%	-5.76%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-03	RIEDEL, NORBERT G	Sale	30,000	—
2026-02-03	RIEDEL, NORBERT G	Buy	30,000	$4.42
2026-01-14	KREMPA, DAVID	Sale	1,942	$15.62

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ETON	$628.09M	35	7.3	4.5	5.0	5.0	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Eton Pharmaceuticals Inc trades at $24.12. Our Smart Value Score of 35/100 indicates the stock is weak. TTM revenue stands at $79.95M. with profit margins at -5.76%.

Frequently asked questions

What is Eton Pharmaceuticals Inc's stock price?

Eton Pharmaceuticals Inc (ETON) trades at $24.12.

Is Eton Pharmaceuticals Inc overvalued?

Smart Value Score 35/100 (Grade D, Sell).

What is the price target of Eton Pharmaceuticals Inc (ETON)?

The analyst target price is $39.33, representing +63.1% upside from the current price of $24.12.

What is Eton Pharmaceuticals Inc's revenue?

TTM revenue is $79.95M.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio7.86x

ROE-18.20%

Beta0.97

50D MA$21.26

200D MA$17.97

Shares out0.03B

Float0.02B

Short ratio—

Avg volume0.4M

Performance

1 week+2.66%

1 month-4.46%

3 months+54.62%

YTD+39.44%

1 year—

3 years—

5 years—

Compare

ETON vs LLY →ETON vs JNJ →ETON vs ABBV →Stock screener →